AlphAIAlphAI — Financial news for AI agents
hcplive.com$NVS

Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events

Novartis' pelacarsen reduced Lp(a) by 78% in the Lp(a)HORIZON trial but did not lower major cardiovascular events. Over 4.7 years, MACE occurred in 12.3% of pelacarsen patients vs 12.1% for placebo. The trial, presented at AHA 2026, included 8322 patients with elevated Lp(a) and cardiovascular disease.

Original reporting
hcplive.com
Published Nov 7, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 6:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events — source image
Source · hcplive.com
Decision brief

The 30-second read

$NVSBearishLow
01

Why it matters

The neutral cardiovascular outcome despite strong biomarker reduction challenges the commercial potential of pelacarsen and may shift R&D focus.

02

Market read

The trial result is a primary disclosure that could move Novartis stock and influence the broader biotech sector's view on Lp(a) therapies.

03

What to watch

The trial highlighted safety tolerability; the lack of efficacy may be due to trial design rather than drug potency.

Relevance 7/10Novelty 8/10Timing: on release day

Background

Pelacarsen is an antisense oligonucleotide from Novartis targeting apolipoprotein(a). The Lp(a)HORIZON trial was a large, global phase 3 study.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis' investigational antisense drug pelacarsen failed to reduce cardiovascular events in the phase 3 Lp(a)HORIZON trial.

Expected impact

downward pressure as investors reassess the Lp(a) program.

Evidence & confidence

The primary endpoint was missed (HR 1.02, p=0.76) despite a 78% Lp(a) reduction, indicating limited near‑term value from the asset.

Market effects

Sector

Lipoprotein(a) therapeutic space may see reduced enthusiasm, affecting other biotech firms pursuing similar approaches.

Regional

US biotech sector could face modest pullback as investors digest the setback.

Global

Limited; primarily impacts Novartis and the niche Lp(a) drug development community.

Counterpoint

What could challenge this read

Some investors may view the Lp(a) reduction as a long‑term asset, betting on future data or combination therapies.

Key entities

  • Company
    Novartis AG

    Developer of pelacarsen, listed on NYSE under NVS.

  • Person
    Steven E. Nissen, MD

    Senior author of the trial results, chief academic officer at Cleveland Clinic.

Read at source← All news

StoryNovartis halts pelacarsen development after phase‑III trial shows no cardiovascular benefit

Related articles

$NVSLow

Novartis Abandons Heart Drug After Surprising Failure in Key Study

Novartis AG is halting development of pelacarsen, an experimental heart drug, after a key study showed no benefit in preventing heart attacks or cardiovascular deaths. The drug, which targets Lp(a), a cholesterol-carrying particle, failed to reduce heart attacks or strokes despite lowering Lp(a) levels. Novartis will continue one trial for a heart valve disease. The company has another experimental drug, DII235, in midstage testing.

osoulmisrmagazine.com
$NVSMed

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.

tradingview.com
$NVSMed

Novartis Cholesterol Drug Fails to Reduce Heart Attacks and Strokes

Novartis' experimental cholesterol drug pelacarsen failed to reduce heart attacks or strokes in a major clinical trial, despite significantly lowering lipoprotein(a) levels. The Horizon trial involved 8,322 participants and was presented at an American Heart Association meeting. Novartis has no further plans for pelacarsen, but other treatments targeting Lp(a) are under investigation.

suaragarut.id
$NVSMed

The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke

Novartis' experimental drug pelacarsen failed to reduce heart attacks or strokes in a clinical trial, despite lowering lipoprotein(a) levels by 78%. The Horizon trial, led by Dr. Steven Nissen, included 8,322 participants with high Lp(a) levels. Experts express surprise and disappointment, but note Lp(a) remains a key heart health indicator. Other drugs by Eli Lilly, Amgen, and Silence Therapeutics are in development.

nbcnewyork.com
$NVSHigh

Novartis shelves potential blockbuster pelacarsen as landmark study fails

Novartis AG is halting development of pelacarsen, an experimental cardiovascular drug, after a key study showed it failed to reduce heart attacks or strokes despite lowering cholesterol. The company will continue one mid-stage study for a different heart condition. The Lp(a) HORIZON trial, published in the New England Journal of Medicine, found no clinical benefit from the drug. According to Dr. Steven Nissen, the trial results were neutral, offering no harm or benefit.

investing.com